Mintsje de Boer1, Flora E van Leeuwen2, Michael Hauptmann2, Lucy I H Overbeek3, Jan Paul de Boer4, Nathalie J Hijmering5, Arthur Sernee5, Caroline A H Klazen6, Marc B I Lobbes7, René R W J van der Hulst8, Hinne A Rakhorst9, Daphne de Jong5. 1. Plastic, Reconstructive and Hand-Surgery, Maastricht University Medical Centre, School for Oncology and Developmental Biology, Maastricht, the Netherlands. 2. Department of Epidemiology and Biostatistics, Netherlands Cancer Institute, Amsterdam, the Netherlands. 3. Dutch Nationwide Network and Registry of Histo- and Cytopathology, Houten, the Netherlands. 4. Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 5. Department of Pathology, VU University Medical Centre, Amsterdam, the Netherlands. 6. Department of Radiology, Medisch Spectrum Twente, Enschede, the Netherlands. 7. Department of Radiology and Nuclear Medicine, Maastricht University, Maastricht University Medical Centre, Maastricht, the Netherlands. 8. Plastic, Reconstructive and Hand-Surgery, Maastricht, University Medical Centre, School of Nutrition and Translational, Research in Metabolism, Maastricht, the Netherlands. 9. Department of Plastic, Reconstructive and Hand Surgery, Ziekenhuis Groep Twente/Medisch Spectrum Twente, Enschede, the Netherlands.
Abstract
IMPORTANCE: Breast implants are among the most commonly used medical devices. Since 2008, the number of women with breast implants diagnosed with anaplastic large-cell lymphoma in the breast (breast-ALCL) has increased, and several reports have suggested an association between breast implants and risk of breast-ALCL. However, relative and absolute risks of breast-ALCL in women with implants are still unknown, precluding evidence-based counseling about implants. OBJECTIVE: To determine relative and absolute risks of breast-ALCL in women with breast implants. DESIGN, SETTING, AND PARTICIPANTS: Through the population-based nationwide Dutch pathology registry we identified all patients diagnosed with primary non-Hodgkin lymphoma in the breast between 1990 and 2016 and retrieved clinical data, including breast implant status, from the treating physicians. We estimated the odds ratio (OR) of ALCL associated with breast implants in a case-control design, comparing implant prevalence between women with breast-ALCL and women with other types of breast lymphoma. Cumulative risk of breast-ALCL was derived from the age-specific prevalence of breast implants in Dutch women, estimated from an examination of 3000 chest x-rays and time trends from implant sales. MAIN OUTCOMES AND MEASURES: Relative and absolute risks of breast-ALCL in women with breast implants. RESULTS: Among 43 patients with breast-ALCL (median age, 59 years), 32 had ipsilateral breast implants, compared with 1 among 146 women with other primary breast lymphomas (OR, 421.8; 95% CI, 52.6-3385.2). Implants among breast-ALCL cases were more often macrotextured (23 macrotextured of 28 total implants of known type, 82%) than expected (49 193 sold macrotextured implants of total sold 109 449 between 2010 and 2015, 45%) based on sales data (P < .001). The estimated prevalence of breast implants in women aged 20 to 70 years was 3.3%. Cumulative risks of breast-ALCL in women with implants were 29 per million at 50 years and 82 per million at 70 years. The number of women with implants needed to cause 1 breast-ALCL case before age 75 years was 6920. CONCLUSIONS AND RELEVANCE: Breast implants are associated with increased risk of breast-ALCL, but the absolute risk remains small. Our results emphasize the need for increased awareness among the public, medical professionals, and regulatory bodies, promotion of alternative cosmetic procedures, and alertness to signs and symptoms of breast-ALCL in women with implants.
IMPORTANCE: Breast implants are among the most commonly used medical devices. Since 2008, the number of women with breast implants diagnosed with anaplastic large-cell lymphoma in the breast (breast-ALCL) has increased, and several reports have suggested an association between breast implants and risk of breast-ALCL. However, relative and absolute risks of breast-ALCL in women with implants are still unknown, precluding evidence-based counseling about implants. OBJECTIVE: To determine relative and absolute risks of breast-ALCL in women with breast implants. DESIGN, SETTING, AND PARTICIPANTS: Through the population-based nationwide Dutch pathology registry we identified all patients diagnosed with primary non-Hodgkin lymphoma in the breast between 1990 and 2016 and retrieved clinical data, including breast implant status, from the treating physicians. We estimated the odds ratio (OR) of ALCL associated with breast implants in a case-control design, comparing implant prevalence between women with breast-ALCL and women with other types of breast lymphoma. Cumulative risk of breast-ALCL was derived from the age-specific prevalence of breast implants in Dutch women, estimated from an examination of 3000 chest x-rays and time trends from implant sales. MAIN OUTCOMES AND MEASURES: Relative and absolute risks of breast-ALCL in women with breast implants. RESULTS: Among 43 patients with breast-ALCL (median age, 59 years), 32 had ipsilateral breast implants, compared with 1 among 146 women with other primary breast lymphomas (OR, 421.8; 95% CI, 52.6-3385.2). Implants among breast-ALCL cases were more often macrotextured (23 macrotextured of 28 total implants of known type, 82%) than expected (49 193 sold macrotextured implants of total sold 109 449 between 2010 and 2015, 45%) based on sales data (P < .001). The estimated prevalence of breast implants in women aged 20 to 70 years was 3.3%. Cumulative risks of breast-ALCL in women with implants were 29 per million at 50 years and 82 per million at 70 years. The number of women with implants needed to cause 1 breast-ALCL case before age 75 years was 6920. CONCLUSIONS AND RELEVANCE: Breast implants are associated with increased risk of breast-ALCL, but the absolute risk remains small. Our results emphasize the need for increased awareness among the public, medical professionals, and regulatory bodies, promotion of alternative cosmetic procedures, and alertness to signs and symptoms of breast-ALCL in women with implants.
Authors: Erin L Doren; Roberto N Miranda; Jesse C Selber; Patrick B Garvey; Jun Liu; L Jeffrey Medeiros; Charles E Butler; Mark W Clemens Journal: Plast Reconstr Surg Date: 2017-05 Impact factor: 4.730
Authors: Piers Blombery; Ella R Thompson; Kate Jones; Gisela Mir Arnau; Stephen Lade; John F Markham; Jason Li; Anand Deva; Ricky W Johnstone; Amit Khot; H Miles Prince; David Westerman Journal: Haematologica Date: 2016-05-19 Impact factor: 9.941
Authors: Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe Journal: Blood Date: 2016-03-15 Impact factor: 22.113
Authors: Mintsje de Boer; Wouter B van der Sluis; Jan P de Boer; Lucy I H Overbeek; Flora E van Leeuwen; Hinne A Rakhorst; René R W J van der Hulst; Nathalie J Hijmering; Mark-Bram Bouman; Daphne de Jong Journal: Aesthet Surg J Date: 2017-09-01 Impact factor: 4.283
Authors: Alexandra Thomas; Brian K Link; Sean Altekruse; Paul A Romitti; Mary C Schroeder Journal: J Natl Cancer Inst Date: 2017-06-01 Impact factor: 13.506
Authors: Garry S Brody; Dennis Deapen; Clive R Taylor; Lauren Pinter-Brown; Sarah Rose House-Lightner; James S Andersen; Grant Carlson; Melissa G Lechner; Alan L Epstein Journal: Plast Reconstr Surg Date: 2015-03 Impact factor: 4.730
Authors: Daphne de Jong; Wies L E Vasmel; Jan Paul de Boer; Gideon Verhave; Ellis Barbé; Mariel K Casparie; Flora E van Leeuwen Journal: JAMA Date: 2008-11-05 Impact factor: 56.272
Authors: Peter G Cordeiro; Paola Ghione; Andy Ni; Qunying Hu; Nivetha Ganesan; Natasha Galasso; Ahmet Dogan; Steven M Horwitz Journal: J Plast Reconstr Aesthet Surg Date: 2020-01-20 Impact factor: 2.740
Authors: Zhen-Yu Wu; Hyun Ho Han; Hee Jeong Kim; Jong Won Lee; Il Yong Chung; Jisun Kim; Sae Byul Lee; Byung-Ho Son; Jin Sup Eom; Jae Ho Jung; Sung- Bae Kim; Gyungyub Gong; Hak Hee Kim; Sei -Hyun Ahn; BeomSeok Ko Journal: Breast Cancer Res Treat Date: 2021-03-19 Impact factor: 4.872
Authors: Elaine S Jaffe; Binita S Ashar; Mark W Clemens; Andrew L Feldman; Philippe Gaulard; Roberto N Miranda; Aliyah R Sohani; Timothy Stenzel; Sung W Yoon Journal: J Clin Oncol Date: 2020-02-11 Impact factor: 44.544
Authors: Julian Kricheldorff; Eva Maria Fallenberg; Christine Solbach; Claudia Gerber-Schäfer; Christoph Rancsó; Uwe von Fritschen Journal: Dtsch Arztebl Int Date: 2018-09-21 Impact factor: 5.594
Authors: Zeynep Akdeniz Dogan; Roberto N Miranda; Swaminathan Iyer; Ralph E Steiner; Prachee Singh; Mark W Clemens Journal: Aesthet Surg J Date: 2020-03-23 Impact factor: 4.283
Authors: Andrés E Quesada; L Jeffrey Medeiros; Mark W Clemens; Maria C Ferrufino-Schmidt; Sergio Pina-Oviedo; Roberto N Miranda Journal: Mod Pathol Date: 2018-09-11 Impact factor: 7.842